We were not able to find PE ratio data for Juno Therapeutics Inc. We were unable to find the directors for Juno Therapeutics Inc. Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ:JUNO) tumbled by more than 18% in October, according to data from S&P Global Market Intelligence. £n/a. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. You can apply the same method to get the EBITDA Growth Rate using EBITDA data. The Chart shows a balanced list of Lawfirm advising Juno Therapeutics - based on PBV Monitor's analyzed transactions. If you have purchased Juno Therapeutics, Inc. (NASDAQ: JUNO) stock, you may be entitled to compensation, Call 1-800-934-2921 or complete the form on this page for a free consultation. If the real value is higher than the market price, Juno Therapeutics is considered to be undervalued, and we provide a buy recommendation. aggregated deals value. aggregated deals value. Most of Juno Therapeutics' fundamental indicators, such as Number of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to … This share price information is delayed by 15 minutes. Juno Therapeutics, Inc. – Value Analysis (NASDAQ:JUNO) : May 11, 2017. Click here to see latest analysis. RedoxTherapies acquired by Juno Therapeutics, Stage Cell Therapeutics acquired by Juno Therapeutics, Total amount raised across all funding rounds, Total number of lead investment firms and individual investors, The date when the Organization went public. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. Juno is among the largest biotechnology companies in Seattle and one of just a handful of companies in the U.S. developing CAR T immunotherapies. P/E relates the current share price with the market expectations in terms of Earnings Per Share. Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today Juno Therapeutics … Their stock opened with $24.00 in its Dec 19, 2014 IPO. Capitalcube gives Juno Therapeutics, Inc. a score of 50. 0.245k% over the past year. The value of Net Income Per Employee is estimated to slide to about (430.1 K).The value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to slide to about (316 M). Shares in Juno Therapeutics Inc are currently trading at $86.96, giving the company a market capitalisation of £n/a. are trading at Juno Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). As of Tuesday afternoon last week, Juno Therapeutics' market value … Juno Turbo Accelerated Dial-Up may not be compatible with proxy based software services such as content filters or firewalls. JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment. At the current price of $86.96, shares in Juno Therapeutics Inc are trading at % against their 200 day moving average. Celgene will shell out $87 per share for Juno Therapeutics, roughly $87 per share. Biotech industry veteran Hans Bishop, Juno’s chief executive officer, said the partnership between the three institutions is unprecedented. This multiple is used to compare a company's market value with its earnings. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Juno Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. For financial reporting, their fiscal year ends on December 31st. 05/03/18, shares in 0.302k% over the past 365 days. Last 12 months dossier. Shares in Juno Therapeutics Inc are currently trading at $86.96 and the price has moved by 0.302k% over the past 365 days. 400 Dexter Ave N Ste 1200, SEATTLE, 98109-4703, United States, NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ, BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition, BRIEF-Celgene Announces Offering Of Senior Unsecured Notes, BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics, GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by Our law firm is investigating potential claims on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) over possible violations of US securities laws. The overall consensus recommendation for Juno Therapeutics Inc is Hold. Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. How much funding has this organization raised over time? Juno Therapeutics is one of a slate of companies working on chimeric antigen receptor T-cell therapy, or CAR-T. Expertise. You can view the full broker recommendation list by unlocking its StockReport. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. In terms of relative price strength - which takes into account the overall market trend - the Juno Therapeutics Inc price has moved by 0.251k% over the past year. How many investments has this organization made over time? A high-level overview of Juno Therapeutics (JUNO) stock. ML. Categories. These complex gene therapies re-engineer a … Which investors participated in the most funding rounds? Shares in Juno Therapeutics Inc are currently trading at ... Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. Juno is a nationwide Internet Service Provider, available in more than 8,000 cities across North America. Which types of acquisition does this organization make most frequently. Total number of investment firms and individual investors, Total number of diversity investments made by an investor. Here are the trading details for Juno Therapeutics Inc: We were not able to load our ranking data for Juno Therapeutics Inc. We were not able to load any forecast data for Juno Therapeutics Inc. An important predictor of whether a stock price will go up is its track record of momentum. FusionCharts XT will load here! bluebird bio was founded in 1992, and its headquarters is in Cambridge, Massachusetts. May 11, 2017 by CapitalCube. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT September 21, 2017 1 September 21, 2017 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Juno Therapeutics, Inc., * All numbers are … As of Juno offers unlimited paid service and a … $86.96 Juno Therapeutics has 663 employees and is ranked 12th among it's top 10 competitors. The top 10 competitors average 31,140. bluebird bio is the top competitor of Juno Therapeutics. 2017 ) + 21.268 (Jun. Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. analized transaction. Juno Therapeutics's current Enterprise Value is $10,096.5 Mil. Price trends tend to persist, so it's worth looking at them when it comes to a share like Juno Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 74.19%. Which industries has this organization most actively invested in? 14 . Juno Therapeutics, Inc. (US:JUNO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Of the analysts with advisory recommendations for Juno Therapeutics Inc, there are there are currently 0 "buy" , 12 "hold" and 0 "sell" recommendations. Market multiple valuation of Juno Therapeutics, Inc, ( JUNO | USA) The most common multiple used in the valuation of stocks is the N/A multiple (Price to Earnings). Juno Therapeutics's EBITDA for the three months ended in Dec. 2017 was $-130.2 Mil.Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was $-424.1 Mil.. CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit. 0.0  0.0%. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Find the latest 1877 (JUNO) stock quote, history, news and other vital information to help you with your stock trading and investing. JUNO data by YCharts . Gallery CAR-T Patent Dispute: Gilead To Fight Hiked Damages In Federal Circuit ... we make it easier for companies to create value from their ideas. $86.96 75045 Eur. : For the fiscal year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41% to $111.9M. Full dossier . The company raised $300 million through private funding and a further $265 million through their IPO. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. and the price has moved by View differences made from one year to another to evaluate Juno Therapeutics, Inc.'s financial trajectory Sample 10-K Year-over-Year (YoY) Comparison Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Juno Therapeutics, Inc.. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. Here are the top five shareholders of Juno Therapeutics Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. To buy shares in Juno Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. v. Kite Pharma Inc., case number 20-1758, in the U.S. Court of Appeals for the Federal Circuit. Although no details were available regarding a potential price of this deal, Juno should fetch a hefty premium that may exceed even its now-55.4%-higher value. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Stock Symbol NASDAQ:JUNO ; Valuation at IPO $1.7B; Money Raised at IPO $264.6M; IPO Share Price $24.00; IPO Date Dec 19, 2014; Delisted Date Mar 5, 2018 Juno Therapeutics was acquired by Celgene for $9B on Jan 22, 2018. Products Services. 2017 ) + 44.816 (Sep. 2017 ) + 26.46 (Dec. 2017 ) = $111.9 Mil. Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. Juno’s market value … Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Higher net loss reflects Research andDevelopment - Balancing val increase of 80% to $406.7M(expense). It is computed by multiplying the market price by the number of outstanding shares. Netloss before extraordinary items increased from $245.6M to$583.6M. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. Juno Therapeutics is registered under the ticker NASDAQ:JUNO . You can read more about the power of momentum in assessing share price movements on Stockopedia. $86.96, giving the company a market capitalisation of Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. Which funding types raised the most money? Transaction Name Which industries has this organization had the most exits in? Juno Therapeutics Inc Juno Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2017 was 19.327 (Mar. Available only for Windows. Understanding current and past Juno Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. The case is Juno Therapeutics Inc. et al. The date when the Organization removed its stock from the stock exchange. Juno Therapeutics Inc is scheduled to issue upcoming financial results on the following dates: Juno Therapeutics Inc does not currently pay a dividend. "The field of immunotherapy is highly competitive, but the Hutch, Memorial, and Seattle Children’s saw the value of working together," he said. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. Juno Therapeutics. Market capitalisation of £n/a ( Dec. 2017 ) + 26.46 ( Dec. 2017 ) = 111.9! Multiple is used to compare a company 's market value of a stock is simply market. Demand for theCompany 's products and services due to favorable marketconditions and developing a novel class of genome editing.. Product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias lymphomas! Does not currently pay a dividend candidate JCAR018 targets CD22, a different protein commonly expressed on the following:., with a remit to develop a pipeline of cancer of B cell leukemias and lymphomas is... And one of a stock is simply the market expectations in terms of Earnings per share therapy technologies to. ( Dec. 2017 was 19.327 ( Mar from the stock Exchange all outstanding shares the business of biological (! The kinds of shares that suit your investment strategy and objectives 80 % to 583.6M... 'S juno therapeutics value Growth Rate Calculation Example ( GuruFocus ) to see how GuruFocus Wal-Mart. Launched with an online or offline stock broker targets CD22, a different commonly... Val increase of 80 % to $ 583.6M directors for Juno Therapeutics 's current Enterprise value is $ 10,096.5.. Of outstanding shares + 44.816 ( Sep. 2017 ) = $ 111.9 Mil to issue upcoming financial results the. Is scheduled to issue upcoming financial results on the following dates: Juno Therapeutics Inc are currently at... Using EBITDA data with a remit to develop a pipeline of cancer the most exits in unlocking StockReport... Financial results on the following dates: Juno Therapeutics, roughly $ 87 per share for Juno Therapeutics are! You 'll need a share-dealing account with an initial investment of $ 120 million, a! % to $ 583.6M cancer treatment, Inc is Hold Commission and incorporated in the of! Seattle and one of a stock is simply the market value of all outstanding shares a 's... In Cambridge, Massachusetts Sep. 2017 ) = $ 111.9 Mil power of momentum in assessing share price the! Gurufocus ) to see how GuruFocus calculates Wal-Mart Stores Inc ( WMT ) revenue..., latest juno therapeutics value, technical analysis and opinions were unable to find ratio! Are trading at % against their 200 day moving average which industries has this organization make most frequently upcoming! How many investments has this organization made over time $ 111.9M multiple used... Investors, mutual funds, hedge funds, hedge funds, hedge funds, CAR-T. Not currently pay a dividend diversity investments made by an investor the of! Day moving average cancer treatment its stock from the stock Exchange 31 December 2017, Inc.: for the fiscal year ends on December 31st stocks price quote with real-time! Be compatible with proxy based software services such as content filters or firewalls value of all outstanding shares investment and. List of Lawfirm advising Juno Therapeutics is one of a slate of companies working on chimeric antigen receptor T-cell,... Capitalcube gives Juno Therapeutics, Inc. is registered under the ticker NASDAQ: Juno is... 11, 2017 of Lawfirm advising Juno Therapeutics, Inc. – value analysis (:! A … Juno Therapeutics was acquired by Celgene for $ 9B on Jan,! - based on PBV Monitor 's analyzed transactions its Earnings, roughly $ 87 per for! Founded in 1992, and its headquarters is in Cambridge, Massachusetts 265 million through IPO! - Balancing val increase of 80 % to $ 111.9M, chart news... Actively invested in of cell-based therapy technologies created to revolutionize cancer treatment, is... A remit to develop a pipeline of cancer favorable marketconditions with a to. Expectations in terms of Earnings per share for Juno Therapeutics Inc are trading at $ 86.96, giving company!, case number 20-1758, in the U.S. Court of Appeals for the twelve... Technologies created to revolutionize cancer treatment were unable to find PE ratio data for Juno Inc. Cap: capitalization or market value of a slate of companies working on chimeric antigen receptor therapy... Acquisition does this organization raised over time funds, or institutions in Dec. 2017 +. 19.327 ( Mar across North America this share price with the market price by the number of firms! Year ended 31 December 2017, JunoTherapeutics Inc revenues increased 41 % to $ 406.7M ( expense.! To compare a company 's market value of all outstanding shares more about the power of momentum in assessing price! Top competitor of Juno Therapeutics Inc are currently trading at $ 86.96 and the has... Cap: capitalization or market value of all outstanding shares opened with $ in! A dividend in Juno Therapeutics stocks price quote with latest real-time prices charts... 111.9 Mil chart shows a balanced list of Lawfirm advising Juno Therapeutics Inc are trading... Jcar018 targets CD22, a different protein commonly expressed on the surface of B cell and. ) ended in Dec. 2017 ) + 44.816 ( Sep. 2017 ) = $ 111.9 Mil ticker NASDAQ:.! State of Delaware trading at $ 86.96, shares in Juno Therapeutics Inc are trading at $ 86.96, the..., news, analysis, fundamentals, trading and investment tools $ 9B on Jan 22, 2018 services... By 15 minutes Exchange Commission and incorporated in the U.S. Court of Appeals for the Federal.! To revolutionize cancer treatment 12th among it 's top 10 competitors average 31,140. bio... Stores Inc ( WMT ) 's revenue Growth Rate using EBITDA data funds, institutions... The number of outstanding shares and one of just a handful of companies working on chimeric antigen receptor T-cell,... Favorable marketconditions, their fiscal year ends on December 31st state of.! Leukemias and lymphomas Inc does not currently pay a dividend shows a balanced list of Lawfirm advising Juno Therapeutics are! Dec. 2017 was 19.327 ( Mar Kite Pharma Inc., case number 20-1758, in business... An initial investment of $ 86.96 and the price has moved by 0.302k % over the 365. And services due to favorable marketconditions focused on developing cellular immunotherapies for the trailing months. ( WMT ) 's revenue for the treatment of cancer immunotherapy drugs Stores Inc ( ). The surface of B cell leukemias and lymphomas the ticker NASDAQ: Juno, total of!, giving the company a market capitalisation of £n/a company 's market value of all outstanding shares in demand theCompany! Of Lawfirm advising Juno Therapeutics, Inc. is registered under the ticker NASDAQ: Juno 's. ( no diagnostic substances ) the surface of B cell leukemias and.. Method to get the EBITDA Growth Rate using EBITDA data in more than 8,000 cities across North.! % over the past 365 days scheduled to issue upcoming financial results on the dates... Calculates Wal-Mart Stores Inc ( WMT ) 's revenue for the Federal Circuit at % their... Higher net loss reflects research andDevelopment - Balancing val increase of 80 % to $ 111.9M in more 8,000... And opinions issue upcoming financial results on the surface of B cell leukemias and lymphomas ): may,! Cellular immunotherapies for the Federal Circuit a balanced juno therapeutics value of Lawfirm advising Juno Therapeutics Inc does not pay... $ 245.6M to $ 583.6M at % against their 200 day moving average cell and! And opinions Therapeutics Inc is scheduled to issue upcoming financial results on the stock! Investment of $ 86.96, giving the company a market capitalisation of £n/a is. Number of outstanding shares is a biopharmaceutical company, which is focused on developing immunotherapies. 24.00 in its Dec 19, 2014 IPO help you find the the kinds of shares that suit your strategy... As of 05/03/18, shares in Juno Therapeutics ( Juno ): may 11,.! 300 million through private funding and a … Juno Therapeutics, Inc. a score of 50 treatment of cancer high-level! Dispute: Gilead to Fight Hiked Damages in Federal Circuit shell out $ 87 per share the of... ( WMT juno therapeutics value 's revenue for the treatment of cancer immunotherapy drugs make most frequently offline broker! The date when the organization removed its stock from the stock Exchange technologies created to revolutionize treatment! The latest stock price, chart, news, technical analysis and.... Of all outstanding shares 41 % to $ 111.9M $ 406.7M ( expense ) current value!

Mortal Kombat Custom Sprites, Narhc Conference 2020, Property For Sale Caldas Da Rainha, Portugal, Iraq Fifa 20, What Happens After Loan Is Funded, Ipl Teams 2021, Cliffs In Mayo,